MDA (Medical Devices Agency) calls for better resourcing of surveillance controls
This article was originally published in Clinica
There must be concern at the level of resources afforded to [the implementation of post-market surveillance legislation] in many EU member states." This is how David Jefferys, chief executive of the UK Medical Devices Agency, addressed the recent annual meeting of the British Healthcare Trades Association (BHTA), in answer to the industry's concerns at the "variability in performance" of the notified bodies and the quality of imported medical devices, especially in the assistive technologies field.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.